CellFactors of the UK has been awarded a broad US patent covering theimmortalization of human neural stem cells through genetic manipulation. The company says it now intends to start negotiations with genomics and drug discovery companies, with a view to granting licenses to firms working on indications not currently in CellFactors areas of focus. Ian Cubitt, CellFactors' chief executive, told the Financial Times that many companies working on regenerative medicine using stem cells may find they are affected by its patent portfolio.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze